MEET OUR TEAM

Meet the Leadership Behind PhenoNet

At PhenoNet, our impact is driven by more than inno vation—it’s powered by the experienced leadership guiding our mission. Our executive team brings together decades of expertise in neuroscience, biotechnology, clinical research, and pharmaceutical development, united by a commitment to advancing new approaches to the treatment of neuroinflammatory diseases.

From strategic drug development and regulatory navigation to clinical trial design and translational medicine, our leaders have a proven track record of advancing therapies from discovery to clinic.

This multidisciplinary team ensures that every decision is rooted in scientific rigor, patient-focused innovation, and a deep understanding of the complex biology underlying ALS, Alzheimer Disease, and related conditions.

David R. Elmaleh, PhD.

Chairman & Scientific founder

Scientific founder, accomplished leadership in drug development from bench to bedside trials in neurodegenerative diseases.

Malgorzata Szerszeniewska,

MD, President Co-Founder

Easthorn CRO founder, leading hundreds of trials in oncology, neurodegenerative diseases and cardiology.

Atul Gupta, MD

Chief Medical Officer

Physician-scientist with global clinical drug development over 60 clinical trials (Phases I–IV) across therapeutic areas, from early design through regulatory submission.

Laszlo Mindak MD, CSSBB, PMP

QA Director

Laszlo has nearly 20 years of experience in the Life Sciences industry, working with both Pharma and CRO companies. A Medical Doctor, certified PMP, and Six Sigma Black Belt, he specialises in digital transformation, QMS, and computerized systems. His focus is on strategic execution and risk-based quality management.

Elizabeth Stuart PharmD, RAC

Senior Regulatory Affairs

Regulatory professional with over 15 years of global experience in providing strategic and operational input in Regulatory Affairs across various stages of drug development and therapeutic areas, most notably in CNS and rare disease.

Patricia Devenyi

Project Director

Patricia has 20 years of experience in clinical research, specialising in Phase 2 and 3 CNS trials. With a PMP certification and a Master’s in Internal Management, she brings strong leadership and regulatory expertise. Her commitment to safety, compliance, and continuous learning makes her a key asset in advancing new therapies.

Susan Bruggemann, CFO

Finance and operations

Finance and operations professional with 30+ years’ experience in both corporate and biotech startup companies.